Welcome to this week's Chutes and Ladders, our roundup of hirings and firings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter) or Emily Mullin (email | Twitter) and we will feature it here at the end of each week.
CEO John Johnson jumps ship as Dendreon sinks lower
As Dendreon ($DNDN) suffers through $620 million in debt payments and maintains only a skeleton crew, CEO John Johnson has decided to step down. Johnson has been in the position since 2012 as the company's prostate cancer drug Provenge failed to meet expectations among a list of competitors including Medivation ($MDVN) and Johnson & Johnson ($JNJ). But Dendreon is looking for Johnson's successor, and Douglas Watson is the flailing company's new chairman. The survivors are optimistic that the company will still succeed. Story
|
Pharma
> Bristol-Myers Squibb ($BMY) appointed Dr. Giovanni Caforio as its chief operating officer and elected him to the board of directors. Release
> Eli Lilly ($LLY) has appointed Dr. Ora Pescovitz as vice president. Pescovitz was formerly CEO of the University of Michigan Health System. Release
> AMAG Pharmaceuticals ($AMAG) has appointed Melissa Bradford Klug as senior vice president of business development and strategy. Release
> Pharmagen has appointed Russell Skibsted as executive vice president and chief financial officer. Release
> Bioprocess Technology Consultants has appointed Frank Riske as senior consultant and Arthur Ley as consultant, and promoted Julia Adam to director of sales and marketing. Release
Biotech
> Aerie Pharmaceuticals ($AERI) has elected James Mazzo to the company's board of directors. Release
> Foamix has appointed Dave Domzalski as president, Dr. Herman Ellman as vice president of clinical affairs and Alvin Howard as vice president of regulatory affairs. Release
> C4X Discovery has appointed Piers Morgan as chief executive officer. Release
> Dave Jobes has joined Carmot Therapeutics as the company's vice president of business development. Release
> Will Lewis has joined UniQure's ($QURE) supervisory board. Release
> Bioanalytical Systems ($BASI) has appointed Jeffrey Potrzebowski as chief financial officer and James Bourdage as vice president of bioanalytical operations. Release
> Cytori Therapeutics ($CYTX) has appointed Ruud Jona to serve as director of the company. Release
> Dyadic International has appointed Michael Tarnok to the company's board of directors. Tarnok is the chairman of Keryx Biopharmaceuticals ($KERX) and a former senior vice president of Pfizer ($PFE). Release
> Asterias Biotherapeutics has appointed former Pfizer ($PFE) senior executive Pedro Lichtinger as president and chief executive officer. Release
> Scioderm has elected Ronald Nardi as the company's first chief scientific officer. Release
> Aerocrine AB announced that Marshall Woodworth will be appointed as chief financial officer, and Anders Murman will be promoted to chief technology officer. Release
> Solstice Biologics in San Diego has appointed Lou Tartaglia as its new president and CEO and John Borgeson as its CFO. Release
> Amgen ($AMGN) has appointed David Meline as its executive vice president and chief financial officer. Release
> U.K.-based DNA Electronics has appointed Nick McCooke as its chief business officer. Release
> Brainstorm Cell Therapeutics, a stem cell developer out of Israel, appointed Dr. Tony Fiorino as its CEO. Release
> Elizabeth Reed joined Celladon as vice president and general counsel. Release
> Coherus Biosciences named Vince Anicetti as senior vice president of global quality. Release
> Robert Conway joined the ARCA ($ABIO) board of directors as chairman. Release
CRO
> Chiltern International and the Society for Applied Pharmacological Sciences have appointed Dr. Marco Romano as president of SSFA for a three-year term. Release
> Clinipace Worldwide has added Dr. Roger Morgan as executive vice president of global medical affairs. Release